Lantheus (LNTH) Q1 2026 earnings review
A Painful Transition Year: Divestitures and Price Compression Hide Under The Hood
Lantheus is sacrificing near-term profitability to fundamentally restructure its business. While headline GAAP Net Income jumped 62% due to a $59.3M gain from selling its SPECT division, the core operations tell a sobering story. Adjusted Net Income fell 12.5% YoY, and the flagship PYLARIFY franchise shrank 6.5% as price erosion outweighed volume growth. Management explicitly calls 2026 a 'setup year', leaning heavily on the newly acquired Neuraceq ($35.4M) and the future launch of a new PYLARIFY formulation to bridge the gap to 2027. Investors must endure margin compression and declining EPS in the meantime.
🐂 Bull Case
The Alzheimer's imaging agent Neuraceq added $35.4M in the quarter and is guided for 'triple-digit' inorganic growth (140-150%) in 2026. The company is actively expanding its manufacturing footprint by adding 6 PMF sites to meet demand.
FDA approval of PYLARIFY TruVu clears a major hurdle. The Q4 2026 launch promises Transitional Pass-Through (TPT) reimbursement status, effectively leveling the playing field against discounting competitors and protecting the franchise's long-term value.
🐻 Bear Case
Despite management citing a 4% volume increase, PYLARIFY revenue declined 6.5% YoY to $240.9M. The company expects an 8-10% net revenue decline for the franchise in 2026 due to aggressive competitor pricing and the loss of prior reimbursement advantages.
Guidance for FY26 Adjusted EPS of $5.00-$5.25 marks a steep deceleration from FY25's $6.08. Higher R&D spending, launch prep costs, and lost interest income are severely compressing margins before new pipeline assets can contribute in 2027.
⚖️ Verdict: ⚪
Neutral. The strategic pivot to pure-play radiodiagnostics is logically sound, but execution risk is exceptionally high. Lantheus must perfectly execute a rolling transition to PYLARIFY TruVu while defending against aggressive price competition. The wait for the 2027 pipeline payoff will require patience.
Key Themes
The Core Engine is Decelerating
PYLARIFY, the company's cash cow, is flashing red. Revenue fell 6.5% to $240.9M in Q1. Management's narrative that 'volumes are up 4%' contradicts the harsh financial reality: aggressive competitor discounting and the shift to Mean Unit Cost (MUC) reimbursement are relentlessly compressing net prices. Management guides for an 8-10% decline in PYLARIFY revenue for the full year 2026. The franchise cannot grow its way out of this pricing hole with volume alone.
Neuraceq Emerges as the New Growth Lever
Acquired via Life Molecular Imaging, Neuraceq is proving its worth immediately. Generating $35.4M in Q1, it fully offset the loss of the divested SPECT business. Management is targeting 140-150% inorganic growth for 2026, driven by a macro shift in Alzheimer's treatment guidelines and the expansion of the PET Manufacturing Facility (PMF) network from 16 to 22 sites.
PYLARIFY TruVu: The Silver Bullet for 2027
Lantheus received FDA approval for PYLARIFY TruVu, a new formulation that enhances manufacturing efficiency. Crucially, this asset is expected to secure Transitional Pass-Through (TPT) status. In the complex macro environment of Medicare reimbursement, TPT status allows hospitals to bill for the drug separately, neutralizing the aggressive discounting tactics of competitors. A phased geographic launch is set for Q4 2026.
Strategic Pivot: Pure-Play Radiodiagnostics
The sale of the legacy SPECT business to SHINE Technologies closed on Jan 1, 2026, stripping $25M per quarter of stable, low-growth revenue. Concurrently, management announced they are seeking 'value-maximizing alternatives' for their therapeutic pipeline assets (excluding PNT2003). This marks a definitive structural shift: Lantheus is abandoning the crowded therapeutics race to monopolize the diagnostics tollbooth.
Margins Compress Under the Weight of Investment
Adjusted Operating Margin dropped from 38.7% in 25Q1 to 34.2% in 26Q1. R&D spending increased to ~10.4% of revenue (up roughly 200 bps) to support the pipeline, while SG&A remains elevated ahead of four potential FDA approvals. Management is spending heavily to build the 2027 bridge, crushing near-term profitability.
DEFINITY Remains Unshakeable
Amidst the portfolio chaos, DEFINITY (ultrasound enhancing agent) grew 6.8% YoY to $84.6M. Maintaining over 80% market share in its 25th year, it provides a highly reliable cash flow stream to fund the aggressive pipeline development.
Delayed Pipeline Payoff Causes EPS Gap
Despite having up to four potential FDA approvals in 2026 (TruVu, OCTEVY, PNT2003, MK-6240), management explicitly warned there will be 'no meaningful revenue contribution' from new launches this year. The timing gap between current R&D/commercial investment and future revenue realization creates a dead zone for earnings growth in FY26.
Other KPIs
Accelerating. Up 23% YoY from $98.8M in 25Q1. Cash generation remains a massive bright spot, allowing the company to fund its operations, integrate recent acquisitions, and buy back $100M in stock in Q4 25 without tapping its $750M revolver. Cash on hand swelled to $498.6M.
Highly distorted. Up 62.3% YoY, but entirely driven by a $59.3M gain on the sale of the SPECT business. Stripping this out, the core business generated roughly $59.1M in net income, reflecting the severe pricing headwinds on PYLARIFY and higher OpEx.
Guidance
Decelerating. Compared to FY25 reported revenue of $1.54B, this represents a significant top-line contraction. While the divestiture of the SPECT business ($111.4M in FY25) accounts for a portion of the decline, the guidance implies the core business is essentially flat, dragged down by an expected 8-10% decline in PYLARIFY.
Reversing. Down sharply from the $6.08 delivered in FY25. The company faces a margin squeeze from increased R&D (up ~200 bps), higher S&M for upcoming launches, a $9M headwind from lost interest income, and the lack of contribution from 2026 product approvals until 2027.
Key Questions
PYLARIFY Price Floor
You guide to an 8-10% decline in PYLARIFY revenue despite 4% volume growth. Is this price compression linear throughout 2026, or do you see a firm pricing floor emerging before the TruVu launch in Q4?
Therapeutic Alternatives Timeline
With the decision to explore 'value-maximizing alternatives' for the therapeutic pipeline, what is the timeline for these transactions, and how will any potential capital influx be deployed?
POSLUMA Head-to-Head Data
While management dismissed the competitor's head-to-head study design, how are you preparing your salesforce to counter the inevitable marketing noise from these results at ASCO?
TruVu TPT Status Confidence
The entire 2027 recovery narrative relies on PYLARIFY TruVu receiving Transitional Pass-Through status. What specific feedback from CMS gives you confidence this will be granted effectively by October 2026?